肾移植抗体介导排斥反应治疗从消极到靶向的演变
抗体介导排斥反应(AMR)是肾移植失功的主要原因之一。传统治疗多基于小型、常无对照的干预研究。IL-6通路阻断在3期试验中未能预防移植物丢失,抗CD20抗体未显示改善移植物存活,Imlifidase在AMR研究中实验组移植物丢失率更高,终末补体抑制剂在效能不足的试验中疗效不一致,而抗CD38抗体基于2期研究结果成为最有前景的新疗法。
要点
- 抗CD38抗体是目前AMR治疗证据最强的药物类别。
- IL-6通路阻断、抗CD20抗体、Imlifidase在相关研究中未显示明确获益。
- C3抑制剂是补体靶向策略中有前景的方向。
核心结论
- 抗CD38抗体是目前AMR治疗证据最强的药物类别。
研究设计与样本
- 综述性文章,讨论肾移植AMR的靶向治疗进展,未报告系统检索范围。
主要发现
- IL-6通路阻断在3期试验中未能预防移植物丢失。
- 抗CD20抗体未显示改善AMR患者的移植物存活。
- Imlifidase在AMR研究中实验组移植物丢失率更高。
- 终末补体抑制剂在效能不足的试验中疗效不一致。
- 抗CD38抗体基于2期研究鼓励性结果成为最有前景的新疗法。
关键数值与推荐
- 抗CD38抗体在2期研究中显示鼓励性结果。
- C3抑制剂是补体靶向策略中有前景的方向。
临床怎么用
- 抗CD38抗体可作为AMR治疗的重点考虑方向。
- IL-6通路阻断、抗CD20抗体和Imlifidase在AMR中未显示明确获益。
局限性
- 传统AMR治疗研究多为小型且常无对照。
- 部分试验效能不足。
- 多种新疗法的体内试验定量结果尚待报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Antibody-mediated rejection (AMR) is among the leading causes of kidney transplant attrition. Traditional AMR therapy was based on interventional studies that were small and often uncontrolled. Although a blockade of the interleukin (IL)-6 pathway failed to prevent allograft loss in a phase 3 trial, anecdotal evidence had previously suggested potential benefit. Likewise, anti-CD20 antibodies have not been shown to improve AMR outcomes in terms of graft survival. Imlifidase, which cleaves all immunoglobulin Gs, and hence also all donor-specific antibodies, showed a higher rate of graft loss in the experimental group of an AMR study. Terminal complement inhibitors showed inconsistent efficacy in underpowered trials; currently, C3 inhibitors are a promising focus for complement-targeted strategies against AMR. Anti-CD38 antibodies currently represent the most promising novel therapy option for AMR based on encouraging phase 2 study results. We furthermore discuss genetically engineered CD38 knock-out multitarget natural killer cells, expressing anti-B cell maturation antigen (BCMA) CAR, IL-15RF and hnCD16, administered in combination with daratumumab (anti-CD38) in this context. This approach represents a cheaper and safer alternative to chimeric HLA antigen receptor (CHAR) T cell therapy. CHAR T cells showed a high specificity in recognizing their respective target anti-HLA class I B cell receptors in vitro. Quantitative results from in vivo trials are pending. Likewise, we hypothesize the use of bi-specific T cell engagers such as CD19 blinatumomab or BCMA teclistamab for the treatment of AMR. In addition, clinical studies investigating conversion from calcineurin inhibitors to co-stimulation therapies such as anti-CD40L antibodies may reduce dnDSAs and AMR. In summary, anti-CD38 antibodies currently constitute the drug class with the strongest evidence for AMR treatment. To date, most CD38 antibodies have been shown to be safe, even after several years of administration in patients with multiple myeloma.
引用
- Pickl JF, Oberbauer R. Trends in nephrology: from nihilism to targeted treatment of antibody-mediated rejection. Nephrol Dial Transplant. 2026. PMID: 41578965. doi:10.1093/ndt/gfag011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。